Tempus AI (NASDAQ:TEM) Director Nadja West Sells 3,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Nadja West sold 3,000 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $69.00, for a total value of $207,000.00. Following the completion of the sale, the director owned 31,981 shares of the company’s stock, valued at $2,206,689. This trade represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Down 1.2%

NASDAQ TEM opened at $62.27 on Wednesday. The stock’s 50-day moving average price is $55.21 and its 200-day moving average price is $51.87. The company has a market capitalization of $11.24 billion, a P/E ratio of -43.24 and a beta of 3.71. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm’s revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.22) EPS. On average, equities research analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of research reports. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. BTIG Research lifted their target price on Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. HC Wainwright dropped their price target on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and upped their target price for the company from $56.00 to $76.00 in a research note on Tuesday. Finally, Lake Street Capital downgraded Tempus AI to a “hold” rating in a report on Monday, July 20th. Ten equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $67.23.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently modified their holdings of TEM. California State Teachers Retirement System raised its stake in Tempus AI by 6,379.2% in the second quarter. California State Teachers Retirement System now owns 6,977,205 shares of the company’s stock worth $404,189,000 after buying an additional 6,869,519 shares in the last quarter. Voloridge Investment Management LLC boosted its holdings in shares of Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after acquiring an additional 1,039,176 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Tempus AI during the second quarter worth about $54,020,000. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. boosted its stake in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after acquiring an additional 821,490 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.